Status:
COMPLETED
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of nAMD.
- Patients were on a previous anti-VEGF therapy and then switched to brolucizumab.
- Patients remained on brolucizumab for at least 12 months.
- Patients had exactly 360 days or more of follow-up after first brolucizumab injection.
- For BRO cohort only: Patients received at least three injections of brolucizumab during study period.
- For ALT cohort only: Patients received at least two injections of brolucizumab and one injection of another anti-VEGF during the study period.
Exclusion
- For BRO cohort only: Patients who received any other anti-VEGF therapy during the 12-month follow-up period.
- Eyes missing bilaterality information in their nAMD diagnosis.
- Eyes missing bilaterality information in their brolucizumab injections.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 12 2022
Estimated Enrollment :
414 Patients enrolled
Trial Details
Trial ID
NCT06178770
Start Date
December 1 2021
End Date
December 12 2022
Last Update
December 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936